Proposal for KX2-391 (Src Inhibitor, Selleckchem S7434)

Overview of Therapeutic Candidate:
KX2-391 (also known as tirbanibulin in some contexts) is a small‐molecule Src kinase inhibitor developed synthetically as part of a targeted approach to interfere with protein–protein interactions in intracellular signaling pathways. It was discovered and subsequently characterized for its ability to block Src-mediated signaling by binding to Src’s substrate binding (peptide) site instead of the more common ATP-binding pocket, thereby offering a selectivity profile that could reduce off-target toxicity. This places KX2-391 in the broader class of targeted tyrosine kinase inhibitors (TKIs) that have been widely investigated, particularly in cancer therapeutics, where modulation of kinase activity can effectively halt oncogenic signaling cascades. In terms of synthesis and origin, KX2-391’s development builds on decades of structure-activity relationship studies within the Src family, utilizing high-throughput screening and subsequent medicinal chemistry optimization to enhance its binding affinity and selectivity, as exemplified by prior work on similar compounds (Temps, 2020). TKIs in this class have historically been used in oncology and, more recently, for repurposing in non-oncologic indications involving aberrant cellular signaling such as fibrotic diseases (ClinicalTrials.gov, n.d.).

Therapeutic History:
The therapeutic history of KX2-391 and related Src inhibitors primarily originates in the field of oncology, where compounds targeting Src family kinases (SFKs) have been evaluated for their potential to inhibit tumor cell migration, proliferation, and metastasis. Clinical evaluations of KX2-391 have been conducted in phase 1 studies in patients with advanced solid tumors or lymphoma, where its safety, pharmacokinetics, and biological effects were characterized (Roswell Park Cancer Institute, 2007). In addition, other trials have assessed its topical formulation in dermatological conditions such as actinic keratosis, demonstrating that the compound has favorable pharmacokinetic profiles and manageable adverse event profiles in non-systemic applications (Almirall, S.A., 2017). Although the clinical data in oncology and dermatology represent its primary historical uses, there is growing mechanistic rationale to repurpose KX2-391 for fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF). Preclinical studies in animal models of fibrosis (including peritoneal fibrosis) have shown that Src kinase inhibitors can attenuate extracellular matrix deposition and fibroblast activation – a mechanism potentially relevant to IPF pathology (Wang et al., 2017). Despite the fact that KX2-391 itself has not been comprehensively evaluated for IPF in prior clinical trials, the underlying pathway—the Src/FAK axis—has been validated in the literature as a contributor to fibroblast-mediated fibrotic remodeling, thereby providing an impetus for repurposing this agent for pulmonary fibrosis (ClinicalTrials.gov, n.d.).

Mechanism of Action:
Src kinases are non-receptor tyrosine kinases that play a central role in a multitude of signaling pathways controlling cell proliferation, migration, adhesion, and survival. KX2-391 selectively inhibits Src kinase by binding to its substrate-binding (peptide) site rather than the highly conserved ATP-binding pocket, a unique mode of action that distinguishes it from many other Src inhibitors and theoretically allows for improved selectivity and reduced off-target effects (Temps, 2020). This selective inhibition disrupts downstream signaling pathways—including those involving focal adhesion kinase (FAK), STAT3, and other mediators of mechanotransduction—that are critical for fibroblast activation and myofibroblast differentiation. In fibroblasts, Src activation is known to phosphorylate multiple substrates that drive actin cytoskeleton remodeling, focal adhesion turnover, and the upregulation of α-smooth muscle actin (αSMA) expression; these molecular events underpin the development of contractile, collagen-producing myofibroblasts that contribute directly to tissue stiffening in IPF (Li et al., 2020). Furthermore, inhibition of Src has been shown to reduce FAK phosphorylation; since FAK is intricately involved in integrin-mediated signaling and mechanotransduction, its inhibition disrupts the cross-talk between the extracellular matrix and intracellular cytoskeletal dynamics, leading to decreased fibroblast contractility and reduced deposition of collagen (Wang et al., 2017). More specifically, multiple studies have suggested that blocking the Src/FAK axis also results in the downregulation of profibrotic transcriptional pathways, as evidenced by reductions in phosphorylated STAT3—a marker closely associated with fibroblast activation and increased collagen production (Wang et al., 2021). These mechanisms collectively suggest that KX2-391’s molecular interactions dampen the mechanotransduction signals that drive the pathological remodeling seen in IPF (Li et al., 2020).

Expected Effect:
Given the mechanistic rationale outlined above, the expected effect of KX2-391 in the proposed assay is a marked reduction in fibroblast contractility, decreased αSMA expression, and a consequent diminution of collagen deposition when fibroblasts are grown in 3D collagen matrices. In vitro assays would likely reveal that treatment with KX2-391 leads to significant downregulation of key fibrotic markers such as αSMA, collagen I and collagen III, concomitant with inhibition of Src phosphorylation and downstream signaling events such as reduced STAT3 activation (Wang et al., 2021). In such 3D collagen contraction assays—which serve as a surrogate for the in vivo mechanical environment of fibrotic lungs—the drug is hypothesized to mitigate the aberrant mechanotransduction that characterizes fibrotic remodeling. It is known that in fibrotic lung tissues, excessive Src/FAK signaling facilitates actin polymerization and the formation of stress fibers that contribute directly to enhanced contractility and increased tissue stiffness; by inhibiting these pathways, KX2-391 is expected to restore more normal cell–matrix interactions and limit the progression of fibrosis (Li et al., 2020). Moreover, given that Src kinase activity also modulates the nuclear translocation of β-catenin in fibroblasts—a key event in the activation of profibrotic gene transcription—KX2-391 may exert additional antifibrotic effects by blunting the Wnt/β-catenin signaling pathway (Li et al., 2020). Since human lung fibroblasts express high levels of Src kinase and its downstream partners in the context of IPF, the drug’s mode of action is particularly relevant to the cell populations driving fibrogenesis, thereby underscoring the feasibility of its use in such assays and ultimately in clinical settings for IPF (ClinicalTrials.gov, n.d.).

Overall Evaluation:
KX2-391 emerges as a promising candidate for repurposing in the treatment of idiopathic pulmonary fibrosis based on its well-characterized mechanism of action, its unique mode of Src inhibition, and the supportive preclinical evidence linking Src/FAK signaling to fibrogenesis. One of the major strengths of KX2-391 lies in its ability to selectively target Src kinase via a non-ATP competitive mechanism, potentially reducing the off-target effects commonly encountered with less selective kinase inhibitors (Temps, 2020). This specificity is particularly appealing given that the pathological processes in IPF are multifactorial, and minimizing unwanted systemic effects is critical. Furthermore, the clinical evaluation of KX2-391 in oncology and dermatology has already established important pharmacokinetic and safety parameters, which can accelerate its repurposing pathway for fibrotic diseases (Athenex, Inc., 2007; Almirall, S.A., 2017). Preclinical studies with analogous compounds, including those that inhibit Src/FAK signaling and attenuate fibroblast activation, provide a solid mechanistic basis for expecting similar antifibrotic benefits in IPF (Wang et al., 2017; Li et al., 2020).

However, there are several caveats and challenges that should be acknowledged. Despite strong mechanistic rationale and encouraging preclinical data from related Src inhibitors like saracatinib—which is undergoing evaluation in clinical trials for IPF (National Jewish Health, 2020)—there is currently limited direct evidence for KX2-391’s efficacy in fibrotic models of the lung specifically. Most available preclinical data are extrapolated from studies in alternative fibrosis models (such as peritoneal fibrosis) or from cancer models, and while these data support the general antifibrotic mechanism of Src inhibition, they do not definitively establish clinical efficacy in IPF. In addition, despite its selective targeting of the Src peptide-binding site, potential resistance mechanisms or off-target effects unique to the fibrotic milieu in the lung cannot be ruled out. The pharmacodynamic and pharmacokinetic properties established in oncology might differ in patients with IPF due to variations in tissue distribution, comorbidities, and disease-specific changes in lung architecture (Wang et al., 2021).

Moreover, while the proposed mechanism—namely, blockade of mechanotransduction via inhibition of focal adhesion kinase phosphorylation and actin remodeling—is well supported in the literature, the complex interplay of additional signaling pathways in IPF (including TGF-β, Wnt/β-catenin, and inflammatory mediators) may necessitate a combinatorial therapeutic approach rather than monotherapy with a Src inhibitor (Li et al., 2020). The reduction in αSMA expression and collagen deposition observed in preclinical studies offers an attractive endpoint; however, long-term effects on lung function, disease progression, and survival in IPF patients will need to be evaluated in rigorously designed clinical trials.

In summary, KX2-391 represents a mechanistically sound and therapeutically promising candidate for repurposing in IPF through its inhibition of Src-mediated pathways that regulate fibroblast activation, focusing on mechanotransduction processes that drive pathological tissue remodeling. Its strengths lie in its unique mechanism of Src inhibition, established clinical safety in other indications, and a robust preclinical rationale that aligns with key pathogenic features of IPF (Temps, 2020; Li et al., 2020; Wang et al., 2021). Nevertheless, further direct preclinical studies in lung fibrosis models and early-phase clinical trials specifically addressing IPF are necessary to validate its efficacy and safety in this new indication. Given these considerations, while the repurposing of KX2-391 holds significant promise, a cautious and methodical development strategy will be critical to its successful translation from oncology to fibrotic lung disease (ClinicalTrials.gov, n.d.).

References
Almirall, S.A. (2017). A multi-center study to evaluate the efficacy and safety of KX2-391 ointment 1% on AK on face or scalp (NCT03285477). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03285477

Athenex, Inc. (2007). Evaluation of KX2-391 in patients with advanced malignancies (NCT00658970). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00658970

ClinicalTrials.gov. (n.d.). Clinical trials search: KX2-391 OR Src inhibitor OR Src kinase inhibitor AND Idiopathic Pulmonary Fibrosis OR pulmonary fibrosis. Retrieved from https://clinicaltrials.gov

Li, X., Liu, X., Deng, R., Gao, S., Yu, H., Huang, K., Jiang, Q., Liu, R., Li, X., Zhang, L., Zhou, H., & Yang, C. (2020). Nintedanib inhibits Wnt3a-induced myofibroblast activation by suppressing the Src/β-catenin pathway. Frontiers in Pharmacology, 11, Article 310. https://doi.org/10.3389/fphar.2020.00310

National Jewish Health. (2020). Saracatinib in the treatment of idiopathic pulmonary fibrosis (NCT04598919). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04598919

Roswell Park Cancer Institute. (2007). KX2-391 in treating patients with advanced solid tumors or lymphoma that did not respond to treatment (NCT00646139). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00646139

Temps, C. (2020). Preclinical investigation of the novel Src inhibitor ECF506 in cancer. https://doi.org/10.7488/era/279

Wang, J., Wang, L., Xu, L., Shi, Y., Liu, F., Qi, H., Liu, N., & Zhuang, S. (2017). Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition. Oncotarget, 8, 83872–83889. https://doi.org/10.18632/oncotarget.20040

Wang, X., Ren, R., Xu, Z., Huang, H., Jiang, W., & Ma, J. (2021). Tirbanibulin attenuates pulmonary fibrosis by modulating Src/STAT3 signaling. Frontiers in Pharmacology, 12, Article 693906. https://doi.org/10.3389/fphar.2021.693906
